Bactericidal activity of gatifloxacin (AM-1155) against Pseudomonas aeruginosa and Enterococcus faecalis in an in vitro bladder model simulating human urinary concentrations after oral administration

Citation
S. Takahashi et al., Bactericidal activity of gatifloxacin (AM-1155) against Pseudomonas aeruginosa and Enterococcus faecalis in an in vitro bladder model simulating human urinary concentrations after oral administration, CHEMOTHERA, 46(2), 2000, pp. 122-128
Citations number
11
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
CHEMOTHERAPY
ISSN journal
0009-3157 → ACNP
Volume
46
Issue
2
Year of publication
2000
Pages
122 - 128
Database
ISI
SICI code
0009-3157(200003/04)46:2<122:BAOG(A>2.0.ZU;2-K
Abstract
The bactericidal activity of gatifloxacin, a new 6-fluoro-8-methoxy quinolo ne, was determined in a dynamic in vitro model mimicking complicated lower urinary tract infection. Strains of Pseudomonas aeruginosa and Enterococcus faecalis with different susceptibility were exposed to changing gatifloxac in concentrations, simulating human urinary concentrations afer oral treatm ent with 200 mg twice daily for 3 consecutive days. Bacterial numbers of P. aeruginosa (minimal inhibitory concentrations, MIG: less than or equal to 32 mu g/ml) and of E. faecalis (MIC: 16 mu g/ml) were reduced to undetectab le levels during exposure. For the strains with lower susceptibility, gatif loxacin showed bactericidal activity, but eradication was not complete. Thu s, in a complicated urinary tract infection model, breakpoint MICs of gatif loxacin for uropathogenic organisms were presumed to range from 16 to 32 mu g/ml. At least 86% of recent clinical isolates of P. aeruginosa and E. fae calis were inhibited at its breakpoint MIG. These results suggest that gati floxacin may be useful in the treatment of urinary tract infections. Copyri ght (C) 2000 S.Karger AG, Basel.